CAMBRIDGE, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying,
Read moreCAMBRIDGE, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying,
Read moreCAMBRIDGE, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying,
Read moreCAMBRIDGE, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying,
Read moreCAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying,
Read moreCAMBRIDGE, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying,
Read moreCAMBRIDGE, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying,
Read moreAppointment strengthens leadership team ahead of tebipenem HBr’s potential commercialization CAMBRIDGE, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) — Spero Therapeutics,
Read moreAppointment strengthens leadership team ahead of tebipenem HBr’s potential commercialization CAMBRIDGE, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) — Spero Therapeutics,
Read moreCAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying,
Read more